Silence Therapeutics Agrees to 1.3 Billion USD Acquisition by Merck KGaA

October 20, 2026 – United Kingdom-based Silence Therapeutics agreed to be acquired by Germany-based Merck KGaA in an all-cash transaction valuing the biopharmaceutical company's equity at approximately 1.3 billion USD.

The definitive agreement centers on Silence's proprietary RNA interference platform and its lead clinical candidate, divesiran, which recently delivered highly positive clinical trial data.

For macroeconomic allocators, the buyout highlights continued aggressive consolidation within the global biotechnology sector as major pharmaceutical companies deploy capital to acquire derisked late-stage clinical assets.

Trading desks observe that shares of Silence Therapeutics trading on the Nasdaq under the ticker SLN surged 125.58 percent to close at 19.58 USD following the formal announcement on October 19.

Transaction Details and Valuations

The German pharmaceutical enterprise will pay 20 USD in cash per American Depositary Share and 6.6667 USD per ordinary share to execute the buyout.

This all-cash offer represents a massive 130 percent premium to the stock's closing price of 8.68 USD recorded on Friday, October 16.

Quantitative analysts note that the transaction assigns the target company an enterprise value of roughly 1.1 billion USD.

Following the announcement, trading volume for the stock exploded to roughly 44.6 million shares, representing a staggering increase compared to its recent 30-session average of roughly 1 million shares.

Clinical Pipeline and Regulatory Pathway

Merck KGaA is primarily pursuing the acquisition to gain full control of dives Iran, a Phase 3-ready therapy designed to treat polycythemia vera, a rare blood disorder.

Recent Phase 2 clinical data demonstrated that dives Iran achieved an 88 percent response rate in patients, vastly outperforming the 19 percent response rate recorded for those on a placebo.

The acquisition itself is structured as a United Kingdom scheme of arrangement under Part 26 of the Companies Act 2006, requiring a shareholder vote and sanction by the High Court of Justice of England and Wales.

Securityholders representing approximately 14 percent of the company's voting power have already signed formal agreements to support the strategic merger.

Asset managers expect the transaction to officially close in the 1st quarter of 2027, with a stipulated termination fee of 13 million USD if the deal ultimately collapses.